Adjuvant Therapy in Renal Cell Carcinoma

Jowhra Al Mwaiza^1, , Ayshah Hazzazi¹, Shaikhah Albishi¹, Zainab Almokhareg¹, Nouf Alqlan² and Naflaa Alotaibi¹

¹Nursing, Ministry of Health, Riyadh, Saudi Arabia

²Doctor, Ministry of Health, Riyadh, Saudi Arabia

Cite this paper:
Jowhra Al Mwaiza, Ayshah Hazzazi, Shaikhah Albishi, Zainab Almokhareg, Nouf Alqlan and Naflaa Alotaibi. Adjuvant Therapy in Renal Cell Carcinoma. American Journal of Medical and Biological Research. 2024; 12(2):45-48. doi: 10.12691/ajmbr-12-2-2

Abstract

Renal cell carcinoma (RCC) is characterized by (a) lack of early warning signs, which results in a high proportion of patients with metastases at the time of diagnosis; (b) protean clinical manifestations; and (c) resistance to radiotherapy and chemotherapy. The estimates of new diagnoses and deaths from kidney cancer in the United States during 1996 are 30,600 and 12,000, respectively. RCC occurs nearly twice as often in men as in women. The age at diagnosis is generally older than 40 years; the median age is in the midsixties. The incidence of RCC has been rising steadily. Between 1974 and 1990, there was a 38% increase in the number of patients who had a diagnosis of RCC. This increase was accompanied by a significant improvement in 5-year survival. Both trends are likely the result of improved diagnostic capability. Newer radiographic techniques, including ultrasonography, computed tomography, and magnetic resonance imaging, are detecting kidney tumors more frequently and at a lower disease stage, when tumors can be resected for cure. Surgical treatment is the only curative therapy for localized RCC. Radical nephrectomy remains the mainstay of surgical management, but techniques are being modified. These modifications include partial nephrectomy and resection of vena caval thrombi. In highly selected cases, surgical resection of locally recurrent RCC or of disease at a solitary metastatic site is associated with long-term survival. Metastatic RCC is highly resistant to the many systemic therapies that have been extensively investigated. A minority of patients achieve complete or partial response to interferon, interleukin-2, or both. Response can be dramatic but is rarely durable. Because most patients do not achieve response, these agents are not considered effective treatments for RCC, but the response in some patients indicates the need for continued research on their use. Identification of new agents with better antitumor activity against metastases remains a high priority in clinical investigation of therapy for this refractory disease.

Keywords:
Renal Cell Carcinoma RCC Therapy

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Key Statistics About Kidney Cancer. American Cancer Society. https://www.cancer.org/cancer/kidneycancer/about/key-statistics.html. Published 2022. Accessed September 12, 2022.
[2]	Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer. 2008;113(1):78-83.
[3]	Haifler M, Neheman A, Zisman A. Has Stage Migration in Renal Cancer Run Its Course? A SEER Database Analysis. Clin Genitourin Cancer. 2020;18(4):e368-e373.
[4]	Klaassen Z. ASCO 2021: Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy for Advanced Clear Cell Renal Cell Carcinoma: Results from 42-Month Followup of KEYNOTE-426 ASCO 2021 Kidney Cancer Web site. https://www.urotoday.com/conference-highlights/asco2021/asco-2021-kidney-cancer/130133-asco-2021- pembrolizumab-plus-axitinib-versus-sunitinib-as-firstline-therapy-for-advanced-clear-cell-renal-cell-carcinomaresults-from-42-month-follow-up-of-keynote-426.html. Published 2021. Accessed December 10, 2022.
[5]	Speed JM, Trinh QD, Choueiri TK, Sun M. Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data. Curr Urol Rep. 2017;18(2):15.
[6]	Hafez KS, Novick AC, Campbell SC. Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma. J Urol. 1997;157(6):2067-70.
[7]	Terrone C, Cracco C, Porpiglia F, et al. Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol. 2006;49(2):324-31.
[8]	Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000;163(4):1090-5; quiz 1295.
[9]	Kattan MW, Sternberg CN, Mehmud F, Bhatt K, McCann L, Motzer RJ. Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients with Advanced Renal Cell Carcinoma Treated with Pazopanib. Oncology. 2015;89(4):235-41.
[10]	Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97(7):1663-71.
[11]	Brooks SA, Brannon AR, Parker JS, et al. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol. 2014;66(1):77-84.
[12]	Morgan TM, Mehra R, Tiemeny P, et al. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma. Eur Urol. 2018;73(5):763-9.
[13]	Qu L, Wang ZL, Chen Q, et al. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. Eur Urol. 2018;74(6):756-63.
[14]	Porzsolt F, Messerer D, Hautmann R, et al. Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. A randomized multicenter trial. J Cancer Res Clin Oncol. 1988;114(1):95-100.
[15]	Trump DL, Elson PJ, Borden EC, et al. High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Study. Cancer Treat Rep. 1987;71(2):165-9.
[16]	Pizzocaro G, Piva L, Colavita M, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol. 2001;19(2):425-31.
[17]	Messing EM, Manola J, Wilding G, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol. 2003;21(7):1214-22.
[18]	Clark JW, Smith JW, 2nd, Steis RG, et al. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen. Cancer Res. 1990;50(22):7343-50.
[19]	Atzpodien J, Schmitt E, Gertenbach U, et al. Adjuvant treatment with interleukin-2- and interferon-alpha2abased chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer. 2005;92(5):843-6.
[20]	Aitchison M, Bray CA, Van Poppel H, et al. Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial. Eur J Cancer. 2014;50(1):70-7.
[21]	Eisen T, Frangou E, Oza B, et al. Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. J Clin Oncol. 2020;38(34): 4064-75.
[22]	Haas NB, Manola J, Dutcher JP, et al. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. JAMA Oncol. 2017;3(9):1249-52.
[23]	Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. N Engl J Med. 2016;375(23):2246-54.
[24]	Motzer RJ, Haas NB, Donskov F, et al. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. J Clin Oncol. 2017;35(35):3916-23.
[25]	Gross-Goupil M, Kwon TG, Eto M, et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol. 2018;29(12):2371-78.
[26]	Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renalcell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016;387(10032):2008-16.
[27]	Ryan Cea. EVEREST: Everolimus for renal cancer ensuing surgical therapy—A phase III study (SWOG S0931, NCT01120249). 2022.
[28]	Administration FaD. FDA approves sunitinib malate for adjuvant treatment of renal cell carcinoma. https:// www.fda.gov/ drugs/ resources-informationapproved-drugs/fda-approves-sunitinib-malate-adjuvanttreatment-renal-cell-carcinoma. Published 2017. Accessed September 17, 2022.
[29]	Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584-90.